10:03 PM
Oct 10, 2018
 |  BC Extra  |  Financial News

Gene therapy company Audentes raises $151M

On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million Wednesday through the sale of 5.2 million shares at $29 in a follow-on underwritten by BofA Merrill Lynch, J.P. Morgan, Cowen and Wedbush PacGrow. The price is a 21% discount to Audentes' close of $36.70 on Tuesday, when it...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >